From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.

abstract：:Objectives: To assess the risk of adverse events (AEs) associated with brentuximab vedotin in lymphoma patients.Methods: Articles were retrieved from PubMed, Cochrane, and Clinicaltrials Databases to identify randomized controlled trials (RCTs) comparing brentuximab vedotin with non-brentuximab vedotin in lymphoma pat...

journal_title：Expert opinion on drug safety

authors： Gao S,Zhang M,Wu K,Zhu J,He Z,Li J,Chen C,Qiu K,Yu X,Wu J

更新日期：2020-05-01 00:00:00

abstract：:Introduction: The use of testosterone therapy (TTh) in men with prostate cancer (PCa) is relatively new, and controversial, due to the longstanding maxim that TTh is contraindicated in men with PCa. Scientific advances have prompted a reevaluation of the potential role for TTh in men with PCa, particularly as TTh has ...

journal_title：Expert opinion on drug safety

authors： Morgentaler A,Caliber M

更新日期：2019-11-01 00:00:00

abstract：INTRODUCTION:Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. HCQ has proved to be effective in a number of autoimmune diseases including systemic lupus erythematosus (SLE). Areas covered: In this review the me...

journal_title：Expert opinion on drug safety

authors： Ponticelli C,Moroni G

更新日期：2017-03-01 00:00:00

abstract：:Methadone is an interesting analgesic for multiple reasons. The unique properties of the agent, low cost and widespread availability have led to increases in methadone prescribing. Despite advantages, methadone is challenging to work with, particularly in patients with high opioid requirements. Recent concerns regardi...

journal_title：Expert opinion on drug safety

authors： Swegle JM,Wensel DD

更新日期：2008-01-01 00:00:00

abstract：:Ixabepilone is a semisynthetic analogue of epothilone B, a novel microtubule-stabilizing agent. Preclinical data suggest that its mechanisms of actions are different from those of the most commonly used microtubule-stabilizing agent, paclitaxel. This information in addition to the cytotoxicity of this drug in taxane-r...

journal_title：Expert opinion on drug safety

authors： Gupta D,Mani S

更新日期：2009-01-01 00:00:00

abstract：:Introduction: Psoriasis is a chronic inflammatory systemic disease that affects 2% of the population and is associated with an important physical and physiological burden. About 0.5-2% of psoriatic cases onset during the pediatric age range, and often it's not diagnosed until adulthood. Adalimumab is an antitumor necr...

journal_title：Expert opinion on drug safety

authors： Zangrilli A,Bavetta M,Bianchi L

更新日期：2020-04-01 00:00:00

abstract：INTRODUCTION:Secondary preventative therapies are essential for patients undergoing coronary artery bypass graft (CABG) surgery to optimize perioperative and long-term outcomes. Beta-blockers are commonly used to treat patients with coronary artery disease and congestive heart failure (CHF), but their role for CABG pat...

journal_title：Expert opinion on drug safety

authors： Thaper A,Kulik A

更新日期：2018-08-01 00:00:00

abstract：BACKGROUND:Gallstone disease is common in Western countries. Statins reduce biliary cholesterol secretion and have anti-inflammatory effects, suggesting that they may play a role in reducing the incidence of surgically treated gallstone disease. AIM:To examine a potential association between statin administration and ...

journal_title：Expert opinion on drug safety

authors： Merzon E,Weiss NS,Lustman AJ,Elhayani A,Dresner J,Vinker S

更新日期：2010-07-01 00:00:00

abstract：:Colchicine has been used for over 2000 years. Intravenous (i.v.) colchicine has been used for the treatment of acute gout since the 1950s. I.v. and oral colchicine were 'grandfathered' before the 1969 FDA Phase III trials for drug toxicity became law. Data on toxic reactions are, therefore, based only on passive surve...

journal_title：Expert opinion on drug safety

authors： Schlesinger N

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:Aripiprazole is a third generation antipsychotic approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia. Aripiprazole is available as oral and long-acting injectable (LAI) depot formulations, with a unique mechanism of action comprising partial D2 and serotonin 5-HT1A agon...

journal_title：Expert opinion on drug safety

authors： Preda A,Shapiro BB

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:Reslizumab, a humanized mAb against IL-5, reduces the number of eosinophils in the blood and lungs. Based on efficacy and safety data from pivotal RCTs, reslizumab had been approved for use as an add-on maintenance treatment of severe asthma with an eosinophilic phenotype in adults who have a history of ex...

journal_title：Expert opinion on drug safety

authors： Cazzola M,Matera MG,Levi-Schaffer F,Rogliani P

更新日期：2018-04-01 00:00:00

abstract：INTRODUCTION:Hyperphosphatemia is common in the late stages of chronic kidney disease (CKD) and is associated with elevated parathormone levels, abnormal bone mineralization, extraosseous calcification and increased risk of cardiovascular events and death. Several classes of oral phosphate binders are available to help...

journal_title：Expert opinion on drug safety

authors： Locatelli F,Del Vecchio L,Violo L,Pontoriero G

更新日期：2014-05-01 00:00:00

abstract：OBJECTIVE:Attention deficit hyperactivity disorder (ADHD) is the most common psychiatric childhood disorder. The most commonly used drugs in the treatment of ADHD are methylphenidate (MPH) and atomoxetine (ATX); the former of the two is prescribed in USA more than it is in Western Europe. Some of the most important saf...

journal_title：Expert opinion on drug safety

authors： Capuano A,Scavone C,Rafaniello C,Arcieri R,Rossi F,Panei P

更新日期：2014-09-01 00:00:00

abstract：:The majority of patients with psychogenic non-epileptic seizures (PNES) do not have epilepsy. There are a number of compelling reasons to take these patients off antiepileptic drugs (AEDs), including drug toxicity and teratogenicity, as well as possibly poorer outcome of PNES and increased risk of iatrogenic harm when...

journal_title：Expert opinion on drug safety

authors： Duncan R

更新日期：2006-09-01 00:00:00

abstract：:Self-medication, using non-prescription drugs, is beneficial to patients, healthcare professionals, the pharmaceutical industry and governments. Although many non-prescription medications are effective, misuse and abuse of these products can arise. Monitoring of specific populations and products, in addition to data r...

journal_title：Expert opinion on drug safety

authors： Hughes CM

更新日期：2003-01-01 00:00:00

abstract：:Folic acid supplementation has drawn much attention in recent years for the prevention of Alzheimer's disease and cognitive decline. In this review, the authors describe how current evidence does not support the use of folic acid supplements to protect against cognitive decline. Although a few studies suggest that fol...

journal_title：Expert opinion on drug safety

authors： Schneider JA,Tangney CC,Morris MC

更新日期：2006-07-01 00:00:00

abstract：INTRODUCTION:The number of HIV patients receiving antiretroviral therapy is increasing worldwide, as new infections continue to occur and access to drugs is scaling up in most developing regions. Due to the efficacious nature of combination antiretroviral therapy in most drug-adherent patients, the concerns on the safe...

journal_title：Expert opinion on drug safety

authors： Fernandez-Montero JV,Eugenia E,Barreiro P,Labarga P,Soriano V

更新日期：2013-09-01 00:00:00

abstract：INTRODUCTION:Dolutegravir (DGV) is the newest integrase inhibitor approved for the treatment of HIV-1 infection in both treatment-naive and experienced adults and adolescents. This article reviews the safety of DGV for the treatment of HIV-1 infection. AREAS COVERED:The PubMed database was searched using the keywords ...

journal_title：Expert opinion on drug safety

authors： Keeshin SW,Feinberg J

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Despite the significant advances in the pharmacological and interventional management of patients with cardiovascular disease (CVD) over the last decades, cardiovascular mortality remains the leading cause of death. Large randomized clinical trials have investigated the efficacy and safety of different ant...

journal_title：Expert opinion on drug safety

authors： Romano S,Buccheri S,Mehran R,Angiolillo DJ,Capodanno D

更新日期：2018-10-01 00:00:00

abstract：:The widespread application of protocols using gonadotropin-releasing hormone (GnRH) agonists or antagonists in assisted reproduction treatment has led to an increasing number of pregnancies exposed to these drugs. This issue has raised scepticism as to the safety of these medications, concerning both pregnant women an...

journal_title：Expert opinion on drug safety

authors： Tarlatzis BC,Bili H

更新日期：2004-01-01 00:00:00

abstract：INTRODUCTION:Cardiac injury is one of the most impairing side effects of anticancer treatment. The extension of the range of available drugs, the use of combination regimens and the association with radiation therapy have improved life expectancy; however, they have also caused a rising typology of cardiac toxicities, ...

journal_title：Expert opinion on drug safety

authors： Minoia C,Giannoccaro M,Iacobazzi A,Santini D,Silvestris N,Fioretti A,Oliva S,Guarini A

更新日期：2012-09-01 00:00:00

abstract：:Worldwide, women comprise > 50% of all people living with HIV and the vast majority of these women are of childbearing age. In fact, a significant proportion of these women are identified as HIV-infected during pregnancy. Preventing perinatal transmission has been one of the greatest prevention successes of the HIV ep...

journal_title：Expert opinion on drug safety

authors： Nurutdinova D,Overton ET

更新日期：2009-11-01 00:00:00

abstract：:Anthracyclines are among the most active chemotherapeutic agents in cancer treatment. Although infrequent, cumulative dose-dependent cardiotoxicity is nevertheless a significant side effect of this therapy resulting in reduced cardiac reserve or even frank cardiac failure. Although used in several types of malignancy,...

journal_title：Expert opinion on drug safety

authors： Ng R,Green MD

更新日期：2007-05-01 00:00:00

abstract：INTRODUCTION:Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL® vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe a...

journal_title：Expert opinion on drug safety

authors： Cecco S,Aliberti M,Baldo P,Giacomin E,Leone R

更新日期：2014-04-01 00:00:00

abstract：INTRODUCTION:In the last couple of years, the number of patients with chronic inflammatory rheumatic diseases being treated with TNF α antagonist has increased dramatically. Adalimumab, a fully human monoclonal antibody against TNF α, is one of the most frequently administered TNF α antagonists. Yet, unresolved issues ...

journal_title：Expert opinion on drug safety

authors： Poddubnyy D,Rudwaleit M

更新日期：2011-07-01 00:00:00

abstract：:Psychosis in Alzheimer's disease is common and troublesome. The impact on the quality of life of both patients and caregivers is high and drug treatments raise concern in terms of both efficacy and safety. Therefore, identifying the risk factors that play an important role in the onset of psychosis is mandatory for th...

journal_title：Expert opinion on drug safety

authors： Cancelli I,Beltrame M,D'Anna L,Gigli GL,Valente M

更新日期：2009-09-01 00:00:00

abstract：BACKGROUND:Ximelagatran, the first oral agent in the new class of direct thrombin inhibitors, was withdrawn from the market due to increased rates of liver enzyme elevations in long-term treatments. Despite intensive pre clinical investigations the cellular mechanisms behind the observed hepatic effects remain unknown....

journal_title：Expert opinion on drug safety

authors： Ainscow EK,Pilling JE,Brown NM,Orme AT,Sullivan M,Hargreaves AC,Cooke EL,Sullivan E,Carlsson S,Andersson TB

更新日期：2008-07-01 00:00:00

abstract：BACKGROUND:Critically ill patients receiving parenteral drugs are at an increased risk of exposure to various excipients administered simultaneously and at increased amounts. Hence, we carried out the present study. RESEARCH DESIGN AND METHODS:Patients admitted in the adult, pediatric, and neonatal intensive care unit...

journal_title：Expert opinion on drug safety

authors： Sridharan K,Hasan HM,Al Jufairi M,Al Daylami A,Al Ansari E,Qader AM,Pasha SAA

更新日期：2020-12-01 00:00:00

abstract：INTRODUCTION:Apatinib is an orally administered small-molecule vascular endothelial growth factor receptor 2 inhibitor. It has been approved and indicated for advanced gastric cancer after the failure of two or more lines of systemic therapy in China. Areas covered: This review summarizes the mechanisms, clinical appli...

journal_title：Expert opinion on drug safety

authors： Geng R,Song L,Li J,Zhao L

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Mipomersen is a first-in-class drug indicated as an adjunct to lipid-lowering medications and diet to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC) and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholes...

journal_title：Expert opinion on drug safety

authors： Hovingh K,Besseling J,Kastelein J

更新日期：2013-07-01 00:00:00